Important Notice This website contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, or in different dosages. Nothing contained herein should be considered a solicitation, promotion or advertisement for any drug including the ones under development on this web site. Any information on the products contained herein is not intended to provide medical advice nor should be used as a substitute for the advice provided by your physician or other healthcare provider. I Agree Local Contribution. Global Impact. Changing Tomorrow Day unites Astellas employees worldwide through community service Read More 1 2 3 News Latest Media IR CSR Stories News / Media Jan 09, 2018 Application for Marketing Approval Submitted for Bispecific CD19-directed CD3 T Cell Engager (BiTE® ) Antibody Construct Blinatumomab for Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia in Japan Read More News / Media Dec 20, 2017 Astellas to Present at J.P. Morgan Healthcare Conference Read More News / General News Dec 12, 2017 Astellas Announces First Clinical Data from Phase I Study of Gilteritinib in Combination with Intensive Chemotherapy in Patients Newly Diagnosed with Acute Myeloid Leukemia Read More News / Media Dec 06, 2017 Astellas, the Institute of Medical Science of the University of Tokyo, Chiba University, and Asahi Kogyosha Enter into Collaborative Research Agreement on Rice-based Oral Vaccine “MucoRice” Read More News / Media Dec 01, 2017 Astellas Announces Personnel Change Read More News / Media Dec 01, 2017 Astellas Acquires Mitobridge Under Existing Collaboration Read More View more >> Clinical Trials This website provides access to information from Astellas sponsored clinical trials and the purpose is not to promote or advertise any products. This site includes information regarding products sold by Astellas in certain countries in the world. However, some of those products are not approved by the regulatory authorities of other countries. For details, please refer to the full Legal Disclaimer. Read More UK Modern Slavery Act Slavery and Human Trafficking Statement for financial year ended 31 March 2017 Read More Annual Report Annual Report 2017 Read More Main navigation About Message from CEO Philosophy Vision & Strategy Governance Corporate Information History Board of Directors Top Management Product Introductions Policies & Position Statements Astellas at a Glance Compliance Initiatives Innovation Therapeutic Areas R&D Partnering Responsibility Our Commitment CSR-Based Management Stakeholder Communications CSR Activities in Five Fields Access to Health Awards & Recognition News News Stories Astellas Library Media Contacts Investors Financial Information Stock & Rating Information IR Calendar IR Library Analyst Coverage Cautionary Statement Bottom footer menu SITE MAP PRIVACY POLICY ACCESSIBILITY TERMS OF USE CONTACT US Copyright © 2017 Astellas Pharma Inc. All Rights Reserved.